Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (August 2024)

17 slides from Rockwell Medical's investor presentation, Aug 8, 2024

1. Slide 1: Investor Presentation

   ©) ROCKWELL He MEDICAL ff Investor Presentation August 8, 2024 RMTI Nasdaq

2. Slide 2: Forward-Looking Statements and Non-GAAP Measures

   Forward-Looking Statements and Non-GAAP Measures Certain statements in this presentation may constitute “forward-looking statements" within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, 2024, 2025

3. Slide 3: Rockwell Medical At A Glance

   Rockwell Medical At A Glance * Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Business * Largest supplier of liquid bicarbonate hemodialysis concentrates in the U.S. Overview * Second largest supp

4. Slide 4: Executive Management Team

   Executive Management Team Mark Strobeck, Ph.D. Jesse Neri Megan Timmins President and CEO SVP, Finance EVP, Chief Legal Aquio Asserna= ARUVANT ms Officer and Secretary <aimaiass aramark yr -ASSERTIO= sR One Symphony Mean Zy| aap Zylax TOPAZ Tim T. Chole Heather R. Hunter SVP, Chief Commercial Office

5. Slide 5: Corporate Strategy

   Corporate Strategy C) Be the Global Leader in Hemodialysis Concentrates QO) Provide Customers with the Highest Quality and Most Reliable Products and Services QO) Achieve $100M+ Annual Net Sales and Sustain Profitability QO) Focus on Innovative, Long-Term Growth Opportunities

6. Slide 6: Only Two Major Manufacturers and Suppliers of Concentrates

   Only Two Major Manufacturers and Suppliers of Concentrates Approximately 475,000 patients in the U.S. require in-center hemodialysis annually®). ¢ ao Hemodialysis is a Necessity for End Stage Renal Disease Patients * Each patient receives approximately 3 treatments per week, totaling ~150 in-clinic

7. Slide 7: U.S. In-Center and Acute Care Hemodialysis Concentrates TAM

   U.S. In-Center and Acute Care Hemodialysis Concentrates TAM ~4-6% CAGR driven primarily by increasing number of patients suffering from end-stage kidney disease 2024 2028 ‘SOURCE: CAGR based on “Rockwell Medical: Concentrates Growth Strategy Report”, LE.K. Consulting LLC (2022) © 2024 Rockwell Medic

8. Slide 8: Growth Opportunities and Potential Additional Revenue Streams

   Growth Opportunities and Potential Additional Revenue Streams Geographic Expansion and internationally. Rockwell continues to Increase market share throughout the U.S. ae secure commercial partnerships and seeks additional growth opportunities globally. At Home Treatments At home dialysis and transi

9. Slide 9: Financials and Milestones

   (©ROCKWELL MEDICAL Financials and Milestones

10. Slide 10: Continue to Improve Rockwell's Financial Health

    Continue to Improve Rockwell’s Financial Health Generated Highest Quarterly Revenue and Gross Profit to Date June 30 June 30 Orton, ep Per Shae Anos) pz] esos Net Sales 25.8 18.1 48.5 37.7 46 1.0 7.6 3.6 $ $ $ $ $ $ $ $ $ 0.5 $ (3.0) $ (0.8) 5) (4.4) Net Income (Loss) $ 0.3 $ (3.3) $ (1.4) $ (5.1) $

11. Slide 11: 2023 was a Transformative Year, Raised 2024 Guidance

    2023 was a Transformative Year, Raised 2024 Guidance | NetSales Gross Profit (Loss) Gross Margin ($ in millions) ($ in millions) 14% - 17% $100 $14-$16 S16 $95 $90 $12 $85 $8 $80 $75 $70 $65 2022 2023 -2024/(E) 2022 2023-2024 (E) 2023 © -2024(E) (€) = Estimated © 2026 Rockwell Medical, Inc. © ROCKWE

12. Slide 12: Projects Profitability on an Adjusted EBITDA Basis for FY'24

    Projects Profitability on an Adjusted EBITDA Basis for FY’24 (Sin millions) $(13.8) $(28.4) 2021 2024 (E) {E) = Estimated © 2028 rockwell Mela, I © ROCKWELL MEDICAL

13. Slide 13: Continued Growth Expected in 2025 and Beyond...

    Continued Growth Expected in 2025 and Beyond... —E =a 2025+ 2025 > ~20% cael 2026+ > +25%

14. Slide 14: 2024 Projected Milestones

    2024 Projected Milestones Q Achieve profitability for the full-year 2024 on an adjusted EBITDA basis. Continue to optimize our business through improved processes and expanded automated manufacturing capabilities. Enhance our distribution capabilities through the modernization of our infrastructure

15. Slide 15: Why Invest in Rockwell Medical?

    pe LISTING ANNIVERSapy QROCKWEL Reon RMTI NasdaqListed jl Nasdaq Why Invest in Rockwell Medical? QO) Experienced Management Team O) Large and Growing Market Opportunity C) Revenue-Generating Business QO) Profitable, Strong Financials O) Attractive Valuation © 2024 Rockwell Medical, Inc.

16. Slide 16: www.rockwellmed.com IR@rockwellmed.com

    www.rockwellmed.com IR@rockwellmed.com

17. Slide 17: Reconciliation to GAAP Financial Measures

    Reconciliation to GAAP Financial Measures Non-GAAP Financial Measures To supplement the Company's financial results presented on a U.S. generally accepted accounting principles (“GAAP”) basis, the Company has included information about non-GAAP measures of EBITDA and adjusted EBITDA as useful operat

Rockwell Medical — Investor Presentation (August 2024) on 6ix